Go Pro
→ Trump’s New Currency Reset (From Porter & Company) (Ad)tc pixel Free ARDS Stock Alerts

Aridis Pharmaceuticals (ARDS) Competitors

Aridis Pharmaceuticals logo
$0.0001 0.00 (0.00%)
As of 08/13/2026 01:14 PM Eastern
Compare

ARDS vs. CLVR, SCPS, NAVB, GNCA, and PXMD

Should you buy Aridis Pharmaceuticals stock or one of its competitors? Aridis Pharmaceuticals's main competitors and comparable companies include Clever Leaves (CLVR), Scopus BioPharma (SCPS), Navidea Biopharmaceuticals (NAVB), Genocea Biosciences (GNCA), and PaxMedica (PXMD). Companies are selected based on similarities in market, industry, and size. These companies are all part of the "pharmaceuticals" industry.

How does Aridis Pharmaceuticals compare to Clever Leaves?

Clever Leaves (NASDAQ:CLVR) and Aridis Pharmaceuticals (NASDAQ:ARDS) are both small-cap healthcare companies, but which is the superior investment? We will contrast the two businesses based on the strength of their risk, analyst recommendations, earnings, dividends, media sentiment, valuation, profitability and institutional ownership.

6.9% of Clever Leaves shares are held by institutional investors. Comparatively, 9.6% of Aridis Pharmaceuticals shares are held by institutional investors. 8.2% of Clever Leaves shares are held by insiders. Comparatively, 5.5% of Aridis Pharmaceuticals shares are held by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company will outperform the market over the long term.

In the previous week, Clever Leaves' average media sentiment score of 0.00 equaled Aridis Pharmaceuticals'average media sentiment score.

Company Overall Sentiment
Clever Leaves Neutral
Aridis Pharmaceuticals Neutral

Clever Leaves has a beta of 3816.13, suggesting that its share price is 381,513% more volatile than the broader market. Comparatively, Aridis Pharmaceuticals has a beta of 49.62, suggesting that its share price is 4,862% more volatile than the broader market.

Company Net Margins Return on Equity Return on Assets
Clever LeavesN/A N/A N/A
Aridis Pharmaceuticals N/A N/A N/A

Clever Leaves has higher revenue and earnings than Aridis Pharmaceuticals. Clever Leaves is trading at a lower price-to-earnings ratio than Aridis Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Clever Leaves$17.42M0.00-$17.90M-$12.36N/A
Aridis PharmaceuticalsN/AN/A-$30.37M$0.310.00

Summary

Clever Leaves beats Aridis Pharmaceuticals on 4 of the 7 factors compared between the two stocks.

How does Aridis Pharmaceuticals compare to Scopus BioPharma?

Scopus BioPharma (NASDAQ:SCPS) and Aridis Pharmaceuticals (NASDAQ:ARDS) are both small-cap healthcare companies, but which is the superior stock? We will contrast the two businesses based on the strength of their valuation, institutional ownership, risk, dividends, earnings, profitability, media sentiment and analyst recommendations.

In the previous week, Scopus BioPharma's average media sentiment score of 0.00 equaled Aridis Pharmaceuticals'average media sentiment score.

Company Overall Sentiment
Scopus BioPharma Neutral
Aridis Pharmaceuticals Neutral

Scopus BioPharma has a beta of -0.19, meaning that its share price is 119% less volatile than the broader market. Comparatively, Aridis Pharmaceuticals has a beta of 49.62, meaning that its share price is 4,862% more volatile than the broader market.

Company Net Margins Return on Equity Return on Assets
Scopus BioPharmaN/A N/A N/A
Aridis Pharmaceuticals N/A N/A N/A

9.6% of Aridis Pharmaceuticals shares are held by institutional investors. 5.1% of Scopus BioPharma shares are held by insiders. Comparatively, 5.5% of Aridis Pharmaceuticals shares are held by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock is poised for long-term growth.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Scopus BioPharmaN/AN/A-$11.61MN/AN/A
Aridis PharmaceuticalsN/AN/A-$30.37M$0.310.00

Summary

Aridis Pharmaceuticals beats Scopus BioPharma on 3 of the 4 factors compared between the two stocks.

How does Aridis Pharmaceuticals compare to Navidea Biopharmaceuticals?

Aridis Pharmaceuticals (NASDAQ:ARDS) and Navidea Biopharmaceuticals (NYSE:NAVB) are both small-cap healthcare companies, but which is the better investment? We will compare the two businesses based on the strength of their media sentiment, dividends, risk, analyst recommendations, profitability, institutional ownership, valuation and earnings.

Company Net Margins Return on Equity Return on Assets
Aridis PharmaceuticalsN/A N/A N/A
Navidea Biopharmaceuticals N/A N/A N/A

Aridis Pharmaceuticals has a beta of 49.62, meaning that its share price is 4,862% more volatile than the broader market. Comparatively, Navidea Biopharmaceuticals has a beta of 1.76, meaning that its share price is 76% more volatile than the broader market.

9.6% of Aridis Pharmaceuticals shares are owned by institutional investors. Comparatively, 0.0% of Navidea Biopharmaceuticals shares are owned by institutional investors. 5.5% of Aridis Pharmaceuticals shares are owned by insiders. Comparatively, 43.7% of Navidea Biopharmaceuticals shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock is poised for long-term growth.

Navidea Biopharmaceuticals has higher revenue and earnings than Aridis Pharmaceuticals. Navidea Biopharmaceuticals is trading at a lower price-to-earnings ratio than Aridis Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Aridis PharmaceuticalsN/AN/A-$30.37M$0.310.00
Navidea Biopharmaceuticals$8.13K0.00-$15.18M-$0.21N/A

In the previous week, Aridis Pharmaceuticals' average media sentiment score of 0.00 equaled Navidea Biopharmaceuticals'average media sentiment score.

Company Overall Sentiment
Aridis Pharmaceuticals Neutral
Navidea Biopharmaceuticals Neutral

Summary

Aridis Pharmaceuticals beats Navidea Biopharmaceuticals on 4 of the 7 factors compared between the two stocks.

How does Aridis Pharmaceuticals compare to Genocea Biosciences?

Genocea Biosciences (NASDAQ:GNCA) and Aridis Pharmaceuticals (NASDAQ:ARDS) are both small-cap healthcare companies, but which is the better business? We will compare the two companies based on the strength of their dividends, media sentiment, institutional ownership, profitability, earnings, analyst recommendations, valuation and risk.

Aridis Pharmaceuticals has lower revenue, but higher earnings than Genocea Biosciences. Genocea Biosciences is trading at a lower price-to-earnings ratio than Aridis Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Genocea Biosciences$1.91M0.00-$33.20M-$0.61N/A
Aridis PharmaceuticalsN/AN/A-$30.37M$0.310.00

Aridis Pharmaceuticals' return on equity of 0.00% beat Genocea Biosciences' return on equity.

Company Net Margins Return on Equity Return on Assets
Genocea BiosciencesN/A -182.88% -62.76%
Aridis Pharmaceuticals N/A N/A N/A

0.6% of Genocea Biosciences shares are held by institutional investors. Comparatively, 9.6% of Aridis Pharmaceuticals shares are held by institutional investors. 1.6% of Genocea Biosciences shares are held by insiders. Comparatively, 5.5% of Aridis Pharmaceuticals shares are held by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company will outperform the market over the long term.

In the previous week, Genocea Biosciences' average media sentiment score of 0.00 equaled Aridis Pharmaceuticals'average media sentiment score.

Company Overall Sentiment
Genocea Biosciences Neutral
Aridis Pharmaceuticals Neutral

Genocea Biosciences has a beta of 1.61, indicating that its stock price is 61% more volatile than the broader market. Comparatively, Aridis Pharmaceuticals has a beta of 49.62, indicating that its stock price is 4,862% more volatile than the broader market.

Summary

Aridis Pharmaceuticals beats Genocea Biosciences on 8 of the 9 factors compared between the two stocks.

How does Aridis Pharmaceuticals compare to PaxMedica?

Aridis Pharmaceuticals (NASDAQ:ARDS) and PaxMedica (NASDAQ:PXMD) are both small-cap healthcare companies, but which is the better business? We will contrast the two businesses based on the strength of their valuation, analyst recommendations, media sentiment, dividends, earnings, institutional ownership, risk and profitability.

9.6% of Aridis Pharmaceuticals shares are held by institutional investors. Comparatively, 4.9% of PaxMedica shares are held by institutional investors. 5.5% of Aridis Pharmaceuticals shares are held by insiders. Comparatively, 1.0% of PaxMedica shares are held by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company is poised for long-term growth.

Aridis Pharmaceuticals' return on equity of 0.00% beat PaxMedica's return on equity.

Company Net Margins Return on Equity Return on Assets
Aridis PharmaceuticalsN/A N/A N/A
PaxMedica N/A -3,167.89%-560.35%

PaxMedica is trading at a lower price-to-earnings ratio than Aridis Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Aridis PharmaceuticalsN/AN/A-$30.37M$0.310.00
PaxMedicaN/AN/A-$18.29M-$6.09N/A

In the previous week, Aridis Pharmaceuticals' average media sentiment score of 0.00 equaled PaxMedica'saverage media sentiment score.

Company Overall Sentiment
Aridis Pharmaceuticals Neutral
PaxMedica Neutral

Aridis Pharmaceuticals has a beta of 49.62, indicating that its share price is 4,862% more volatile than the broader market. Comparatively, PaxMedica has a beta of -0.99, indicating that its share price is 199% less volatile than the broader market.

Summary

Aridis Pharmaceuticals beats PaxMedica on 7 of the 8 factors compared between the two stocks.

Get Aridis Pharmaceuticals News Delivered to You Automatically

Sign up to receive the latest news and ratings for ARDS and its competitors with MarketBeat's FREE daily newsletter.

Subscribe Now
SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Skip Chart

ARDS vs. The Competition

Export
MetricAridis PharmaceuticalsPharmaceuticals IndustryHealthcare SectorNASDAQ Exchange
Market Cap$5K$11.89B$7.06B$13.10B
Dividend YieldN/A2.70%2.57%10.45%
P/E Ratio0.00775.15269.0625.28
Price / SalesN/A741.16592.9687.71
Price / CashN/A66.4570.4850.90
Price / BookN/A11.6012.916.24
Net Income-$30.37M$2.77B$3.45B$347.60M
7 Day PerformanceN/A0.17%1.12%1.07%
1 Month PerformanceN/A0.35%1.79%1.03%
1 Year PerformanceN/A161.52%67.69%20.77%

Aridis Pharmaceuticals Competitors List

Export
CompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)
ARDS
Aridis Pharmaceuticals
N/A$0.00
flat		N/AN/A$5KN/A0.0030
CLVR
Clever Leaves
N/A$0.01
flat		N/A-50.0%$18K$17.42MN/A560
SCPS
Scopus BioPharma
N/A$0.00
flat		N/A+33.3%$17KN/AN/A9
NAVB
Navidea Biopharmaceuticals
N/AN/AN/AN/A$10K$8.13KN/A10
GNCA
Genocea Biosciences
N/AN/AN/AN/A$6K$1.91MN/A70

Related Companies and Tools

Related Companies
Top 10 Stock Comparisons

This page (NASDAQ:ARDS) was last updated on 8/14/2026 by MarketBeat.com Staff.
From Our Partners
AI insiders stockpile guns, gold & gas masks
Keith Kaplan, CEO of TradeSmith, has spent more than $17 million studying AI since 2022. He says a major shift...
TradeSmith | Sponsoredtc pixel
Wall Street is staring at the wrong AI trade
Anthropic just signed a 9.1 billion dollar, 20 year data center agreement covering 191 megawatts of capacity, ...
The Oxford Club | Sponsoredtc pixel
Here’s the stock symbol I’ve promised
Whitney Tilson of Stansberry Research has long recommended Berkshire Hathaway as a core retirement holding - b...
Stansberry Research | Sponsoredtc pixel
Trump’s New Currency Reset
Trump is launching a new $250 bill - but that may be a distraction. Behind the scenes, Executive Order 14241 i...
Porter & Company | Sponsoredtc pixel
They didn't warn anyone in 1971. This time someone is warning you.
On August 15, 1971, Nixon interrupted prime-time television and ended the gold standard in 15 minutes - no deb...
Reagan Gold Group | Sponsoredtc pixel
After KDA, PRE, and OCEAN—this is the one
17,556% on KDA. Here's what I'm buying now. It's a coin under $1.00 that most investors have never heard of...
Crypto 101 Media | Sponsoredtc pixel
Your book is inside
The "Sucker's Bet" Most New Options Traders Fall For Most people who try options lose money the same way. ...
Profits Run | Sponsoredtc pixel
CODE RED: AI Meltdown Imminent?
After correctly predicting the 2008 and 2020 stock market meltdowns, I believe this AI company is about to tri...
Paradigm Press | Sponsoredtc pixel